Home | Welcome to Contract Pharma   
Last Updated Saturday, October 25 2014
Print

Financial Report: AbbVie



Published October 25, 2013
AbbVie

3Q Revenues: $4.7 billion (+3%)

3Q Earnings: $964 million (-39%)

YTD Revenues: $13.7 billion (+4%)

YTD Earnings: $3.0 billion (-20%)

Comments: Humira sales were $2.8 billion in the quarter, up 19%. AndroGel and Kaletra sales were down 11% to $248 million and $237 million, respectively. Niaspan sales were down 13% to $201 million. TriCor/Trilipix sales were down 88% to $39 million, due to loss of exclusivity. Synthroid sales were up 23% to $161 million. Creon and Zemplar sales were up 10% to $101 million and $100 million, respectively. R&D expenses were down 12% to $714 million.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On